On June 2, 2021 GeneCentric Therapeutics, a company making precision medicine more precise, reported upcoming data presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, being held virtually June 4th through 8th (Press release, GeneCentric Therapeutics, JUN 2, 2021, View Source [SID1234583377]). The presentations will focus on the ongoing collaborations with Basilea Pharmaceutica International Ltd and their Lisavanbulin Phase 2 clinical program in glioblastoma. Lisavanbulin is a prodrug of the lipophilic small molecule BAL27862, a novel tumor checkpoint controller that promotes tumor cell death by modulating the spindle assembly checkpoint. A key aspect of the current collaboration is the development of biomarkers, including differentially expressed genes, that may predict response to lisavanbulin and could serve as a potential predictive response signature in glioblastoma and other tumor types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentations are as follows:
Title: Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.
Session: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
Date: 4 June 2021
Abstract Number: 3118
Title: The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.
Session: Central Nervous System Tumors
Date: 4 June 2021
Abstract Number: TPS2068
GeneCentric’s RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform and the associated pipeline of response signatures is being leveraged alongside traditional immunohistochemistry (IHC) to better characterize patients most likely to respond to lisavanbulin.
"We are excited to highlight ongoing clinical collaborations and our novel RNA-based technologies at the ASCO (Free ASCO Whitepaper) annual meeting," said Michael Milburn, PhD, GeneCentric President and CEO. " While most conferences have been virtual this past year, GeneCentric has experienced expansive growth in collaborations as well as enhanced interest in our deep expertise in RNA-based genomic solutions which parse out the complexities of tumor biology."